State Street Corp Has $17.24 Million Stake in Fulgent Genetics, Inc. (NASDAQ:FLGT)

State Street Corp boosted its holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 1.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 793,545 shares of the company’s stock after purchasing an additional 10,868 shares during the quarter. State Street Corp owned about 2.59% of Fulgent Genetics worth $17,244,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Asset Dedication LLC acquired a new position in shares of Fulgent Genetics during the second quarter valued at about $33,000. nVerses Capital LLC bought a new position in Fulgent Genetics in the 2nd quarter valued at about $43,000. Signaturefd LLC boosted its stake in Fulgent Genetics by 103.6% during the 2nd quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock valued at $44,000 after purchasing an additional 1,132 shares during the last quarter. Point72 DIFC Ltd bought a new stake in Fulgent Genetics during the 3rd quarter worth approximately $46,000. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Fulgent Genetics in the second quarter worth approximately $63,000. Institutional investors own 48.06% of the company’s stock.

Insider Activity at Fulgent Genetics

In related news, CEO Ming Hsieh sold 2,227 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $18.26, for a total value of $40,665.02. Following the transaction, the chief executive officer now directly owns 703,711 shares of the company’s stock, valued at approximately $12,849,762.86. The trade was a 0.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders sold 3,413 shares of company stock valued at $62,321. 32.66% of the stock is owned by insiders.

Fulgent Genetics Stock Down 0.4 %

Fulgent Genetics stock opened at $18.51 on Wednesday. Fulgent Genetics, Inc. has a 52 week low of $16.56 and a 52 week high of $30.60. The company’s 50 day moving average price is $19.41 and its two-hundred day moving average price is $20.90. The stock has a market cap of $566.17 million, a P/E ratio of -3.35 and a beta of 1.42.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. StockNews.com cut Fulgent Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 27th. Piper Sandler cut their price objective on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a report on Monday, November 11th.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.